Ibrutinib, a covalent inhibitor of Bruton tyrosine kinase (BTK), caused selective and durable downregulation of PD-L1 on chronic lymphocytic leukemia cells within 3 months of therapy, which was mediated through the inhibition of constitutively active STAT3 on these cells [111]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.